Background on COVID-19 Sample Clauses

Background on COVID-19. ‌ In December 2019, a novel coronavirus (subsequently named SARS-CoV2) was detected in 3 patients with pneumonia connected to the cluster of acute respiratory illness cases from Wuhan, China. By the end of February 2020, multiple countries were experiencing sustained local transmission and is now a world-wide pandemic and global health crisis. The most commonly reported clinical symptom in laboratory-confirmed cases was fever (88%), dry cough (68%), fatigue (38%), sputum production (33%), dyspnea (19%), sore throat (14%), headache (14%) and myalgia or arthralgia (15%). Less common symptoms were diarrhea (4%) and vomiting (5%). About 80% of reported cases in China had mild to moderate disease (including non-pneumonia and pneumonia cases), 13.8% had severe disease (as defined in this protocol) and 6.1% were critical (respiratory failure, septic shock, and/or multiple organ dysfunction/failure). Current estimates suggest a median incubation period from 5 to 6 days for SARS-CoV2, with a range from 1 to up to 14 days. A recent modelling study confirmed that it remains prudent to consider the incubation period of up to 14 days. Xxxxxx estimates for final case fatality risk for COVID-19 are still lacking and biased due to incomplete outcome data and the fact that initial detections were of mostly severe cases in most Confidential Page 25 of 74 ‌‌‌‌‌ Activity of Selinexor and other SINE compounds in models of Inflammation and Viral Infection Selinexor (MW 443.3) and verdinexor (MW 442.3) are closely related molecules that differ by one atom. They have similar chemical, pharmacological and pharmacokinetic properties. Both are potent (Ki < 10 nM) and highly selective inhibitors of XPO1. Both compounds form slowly reversible covalent bonds with cysteine-528 of XPO1 leading to its inactivation, and both are orally bioavailable compounds with no known drug-drug interactions. Preclinically, selinexor has been most intensively studied in cell lines and models of neoplastic diseases, whereas verdinexor has been studied most intensively in viral and autoimmune disorders (Appendix 1). Over 200 XPO1 cargo proteins have been identified including proteins with regulatory roles in inflammatory response and many viral proteins including severe acute respiratory syndrome coronavirus (SARS-CoV2) proteins (Zhou 2020). A variety of viruses produce proteins that require nuclear export to carry out their functions. SARS-CoV2, including nucleoprotein (N), protein 9b, Orf6, and potentia...
Sample 1
AutoNDA by SimpleDocs

Related to Background on COVID-19

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • Project Background 6.1.1. Brief description of Contracting Agency’s project background and/or situation leading to this Project

  • Background Data The Disclosing Party's Background Data, if any, will be identified in a separate technical document.

  • General Background In accordance with the Amendment provision in Section 11 of the Registrar, Transfer Agency and Paying Agency Agreement between State Street Bank and Trust Company (the "Bank") and Royce Value Trust, Inc. (the "Fund") dated August 21, 1996 (the "Agreement"), the parties desire to amend the Agreement.

  • Intellectual Property Rights in Construction Documents, Drawings, and Models The drawings, Specifications and other documents prepared by the Design Professional pursuant to this Contract (including, without limitation, the Construction Documents), are the property of the Owner, whether or not the Project for which they are made commences or completes construction. Neither the Contractor nor any Subcontractor or material or equipment supplier shall own or claim a copyright in such drawings, Specifications, and other similar or related documents; Owner shall retain all common law, statutory, and other intellectual property rights with respect thereto. The Contractor must deliver remaining copies of such documents to the Owner upon request or upon completion of the Work, except that the Contractor may keep one copy of such documents for its files. The Contractor shall only use such drawings, Specifications and other documents for this Project. Neither the Contractor nor any Subcontractor or material or equipment supplier may use such drawings, Specifications, and other documents on other projects without the specific written consent of the Owner. All models are the property of the Owner.

  • OBLIGATIONS AND ACTIVITIES OF CONTRACTOR AS BUSINESS ASSOCIATE 1. Contractor agrees not to use or further disclose PHI County discloses to Contractor other than as permitted or required by this Business Associate Contract or as required by law.

  • Claims relating to Intellectual Property Rights 29.1. The Contractor must not infringe any Intellectual Property Rights of any third party in providing the Services or otherwise performing its obligations under the Framework Agreement and must ensure that the provision of the Services and the use or possession of the Deliverables does not infringe such Intellectual Property Rights.

  • Background and Narrative of Budget Reductions 2. Assumptions Used in the Deficit Reduction Plan: - EBF and Estimated New Tier Funding: - Equal Assessed Valuation and Tax Rates: - Employee Salaries and Benefits: - Short and Long Term Borrowing: - Educational Impact: - Other Assumptions: - Has the district considered shared services or outsourcing (Ex: Transportation, Insurance) If yes please explain: ESTIMATED LIMITATION OF ADMINISTRATIVE COSTS (School Districts Only) (For Local Use Only)

  • ACKNOWLEDGEMENT AND PROTECTION OF INTELLECTUAL PROPERTY RIGHTS 9.1 The Institution acknowledges that all copyrights, patent rights, trade marks, database rights, trade secrets and other intellectual property rights relating to the Licensed Material are the sole and exclusive property of Publisher or are duly licensed to the Publisher and that this Licence does not assign or transfer to the Institution any right, title or interest therein except for the right to use the Licensed Material in accordance with the terms and conditions of this Licence.

  • Background IP Each Party will own all right, title and interest in its Background IP.

Time is Money Join Law Insider Premium to draft better contracts faster.